AMBER HARDY: Open Payments
NPI 1497586192 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,171 in 88 payments from 39 companies in 2025. Trend: 2023 $0 · 2024 $359 · 2025 $2,171
Food & beverage: $1,893Education: $278
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 8 | $184 |
| Incyte Corporation | 4 | $160 |
| AstraZeneca Pharmaceuticals LP | 5 | $118 |
| Novartis Pharmaceuticals Corporation | 5 | $117 |
| EMD Serono, Inc. | 5 | $116 |
| Daiichi Sankyo Inc. | 4 | $112 |
| Merck Sharp & Dohme LLC | 4 | $104 |
| SEAGEN INC. | 1 | $100 |
| BeOne Medicines USA, Inc. | 5 | $95 |
| Eisai Inc. | 5 | $90 |
Products named: BRUKINSA, OJJAARA, SARCLISA, Lenvima, Enhertu, KEYTRUDA, KISQALI, CALQUENCE.
Industry payments across LA — which companies pay providers there.
